Psychedelics as a Potential Treatment for Borderline Personality Disorder: A Narrative Review

Abstract

1. Introduction

2. Neurobiology of BPD: Why Psychedelics Are Theoretically Relevant

3. Pharmacological Mechanisms of Candidate Psychedelics

3.1 Classic Serotonergic Hallucinogens (Psilocybin, LSD)

Figure: Hallucinogens including psilocybin, LSD, and mescaline act as 5-HT2A agonists. From Stahl's Essential Psychopharmacology.

3.2 MDMA (Empathogen/Entactogen)

3.3 Ketamine and Esketamine

4. Existing Evidence: What Has Been Studied?

4.1 The Artna et al. (2026) Narrative Review

• Preliminary evidence supports safety and some efficacy for improvement in core BPD symptoms (emotional dysregulation, suicidal ideation) and socio-occupational functioning
• Across all compounds, no evidence of increased risk compared to non-BPD populations when treatment was delivered in controlled, supervised settings
• The included studies were heterogeneous in design (case reports, open-label trials, RCTs not focused on BPD), and almost none used BPD-specific primary outcome measures
• The reviewers concluded that "further high-quality evidence focusing on BPD-specific outcomes is needed"

4.2 MDMA-Assisted Psychotherapy: Theoretical Framework

4.3 Ketamine-Assisted Psychotherapy: Case Evidence

4.4 Broader Psychedelic Efficacy: Systematic Review Evidence

5. Mechanistic Rationale for BPD-Specific Targets

6. Safety Considerations

1. Suicidal ideation and self-harm. The risk of psychedelic-induced psychological distress precipitating suicidal crisis is the most-cited concern. However, ketamine's rapid anti-suicidal properties represent a potential advantage rather than a liability, and the Artna et al. review found no evidence of worsened suicidal outcomes across included studies under controlled conditions.
2. Substance use comorbidity. Rates of substance use disorders (SUD) are elevated in BPD (reported in up to 65% of patients in some series). Most psychedelic trials exclude active SUD, limiting generalizability. However, ketamine is itself being studied specifically for addiction disorders, complicating this calculus.
3. Dissociation. Many BPD patients experience chronic dissociative symptoms. The dissociative effects of ketamine and the depersonalization possible with classic psychedelics could theoretically destabilize patients. The Artna review found that dissociative side effects were not more frequent or severe in BPD patients than in controls when delivered in supervised settings, but careful screening and monitoring are essential.
4. Psychosis risk. BPD is associated with brief stress-induced psychotic episodes. Classic psychedelics can produce psychotomimetic experiences, and the risk of precipitating or prolonging psychotic states requires careful attention. Patients with prominent psychotic features should likely be excluded.
5. Emotional intensity and re-traumatization. The emotional amplification characteristic of psychedelic states may be more intense and less predictable in patients with severe affect dysregulation. "Set, setting, and cast" - the mindset of the patient, the therapeutic environment, and the presence of a trained therapist - are considered critical variables in determining whether the psychedelic experience is therapeutic or harmful. - Stahl's Essential Psychopharmacology, Neuroscientific Basis

7. Current Treatment Landscape and Context

• Emotional lability / rapid cycling: lithium, lamotrigine, valproate, low-dose antipsychotics (olanzapine, aripiprazole, clozapine)
• Affective aggression: SSRIs, anticonvulsants, low-dose antipsychotics
• Cognitive-perceptual distortions / brief psychosis: novel antipsychotics
• Benzodiazepines are generally contraindicated due to disinhibition risk

8. Gaps, Limitations, and Future Directions

• No RCTs have been designed specifically for BPD as the primary indication for any psychedelic compound. All available data are either indirect (from trials that incidentally included patients with BPD features) or observational/case-based.
• BPD-specific outcome measures (e.g., Zanarini Rating Scale for BPD [ZAN-BPD], McLean Screening Instrument, MSI-BPD) are rarely used as primary endpoints. Most studies use generic depression, anxiety, or PTSD scales that do not capture the full BPD symptom constellation.
• Selection bias from exclusion criteria. The very practices that have excluded BPD patients from trials - concerns about suicide, SUD, and emotional instability - have left a research void that mirrors the clinical experience of treating this population.
• Heterogeneity of study designs. The 22 studies in the Artna review span case reports, open-label pilots, and RCTs in comorbid conditions, making any pooled conclusions methodologically challenging.
• Dissociation as a double-edged variable. Whether dissociative side effects in BPD represent a therapeutic window or a risk factor remains unresolved and will require careful sub-group analysis.

1. Phase II RCTs with BPD as the primary indication, using BPD-validated outcome tools (ZAN-BPD, STEPPS scales)
2. MDMA-AP trials combining trauma-focused therapy protocols adapted for BPD (e.g., MDMA augmentation of DBT)
3. Ketamine/esketamine safety and dose-finding studies in BPD with concurrent suicidal ideation
4. Neuroimaging biomarker studies examining whether psychedelics normalize frontolimbic dysconnectivity in BPD
5. Longitudinal studies addressing durability of response and impact on functional outcomes

9. Conclusion

Key References

Disclosure note: The current evidence is preliminary. Psychedelic-assisted therapy for BPD is not an approved or standard-of-care intervention. All cited studies were conducted in supervised clinical settings by trained providers. Patients with BPD considering these approaches should be directed to evidence-based treatments (primarily DBT) while research matures.